DISCLAIMER: CONSULT WITH A DOCTOR BEFORE DECIDING ON A TREATMENT PLAN FOR ANY DISEASE OR INJURY.
Vitamin C can be administered orally, but by receiving intravenous vitamin C treatments, patients can achieve higher blood levels. Vitamin C treatments have been used as a stand-alone treatment for cancer, but a better approach involves a full cancer protocol (including diet therapy and other powerful treatments) that includes vitamin C. It can be used with conventional treatments such as chemotherapy and radiation to improve quality of life.
Intravenous vitamin C is a therapy that’s typically used in conjunction with other cancer treatments, but vitamin C, when administered in very high doses by IV infusion, can kill cancer cells by itself. This treatment should be administered in a treatment facility under the direction of experienced health practitioners. Cancer cells differ metabolically from normal cells in that the mitochondria of faulty cells produce high levels of redox-active iron molecules. These molecules react with vitamin C to produce hydrogen peroxide. Hydrogen peroxide, in turn can damage the DNA of the cancer cells and their mitochondria which ultimately kills the cancer. The vitamin C treatment is selectively toxic against only unhealthy cells .
Vitamin C is a naturally occurring substance that’s found in food and supplements. It’s an anti-oxidant that plays an important role in making collagen and keeping tissues healthy. When vitamin C is given intravenously, it’s possible for it to reach higher concentrations in the blood than what’s possible when vitamin C is taken by mouth .
High doses of intravenous vitamin C in cancer patients generally produces few side effects, though serious side effects are possible. In mainstream medicine, cancer patients who are given high doses of IV vitamin C experience an improved quality of life and fewer side effects from chemotherapy and radiation. Studies have shown that IV therapy with high-doses of vitamin C can improve the effectiveness of standard chemotherapy and radiation treatments. The vitamin C seemed to slow the progression of the disease .
Nine months of high-dose vitamin C treatment via IV costs less than one dose of chemotherapy .
Intravenous vitamin C has not been demonized to the same extent as certain other no-chemo cancer treatments in part because it can be used in tandem with standard treatments such as chemotherapy and radiation. As such, high-dose vitamin C is not as big of a threat to pharmaceutical companies and instead, research funding has been made available to demonstrate its efficacy in prolonging the life of patients with glioblastoma and stage 4 lung cancer . The effectiveness at prolonging lifespan even among patients who followed the standard medical model supports the effectiveness of high-dose vitamin C as a cancer treatment that works despite the presence of the highly toxic biological environment produced by chemo and radiation.
Two studies done by scientists Creagan and Moertel in 1979 at the Mayo Clinic put a spin on high-dose vitamin C treatment, claiming that it was nearly impossible to produce therapeutic concentration levels. In both of these studies, the vitamin C was administered orally, but the medical community was bamboozled by these results and believed that high concentration levels could not be achieved through any means .
The reason why intravenous vitamin C is used to treat cancer rather than orally administered vitamin C is because vitamin C concentrations can be raised safely to high levels using intravenous administration. At high concentration levels, vitamin C is toxic to cancer cells, but beneficial to healthy cells. Vitamin C at high concentrations prevents angiogenesis (or the development of a tumor’s blood supply). As the vitamin accumulates in cancer cells, tumor cells stop growing and inflammation is reduced in the body. Further, patients experience few side effects and adverse events when vitamin C is administered intravenously .
Safety and Effectiveness
Intravenous vitamin C is effective against a variety of cancer types including:
Clinical studies have shown that oral administration of vitamin C at the maximum tolerated dose (18grams/day), produces only a peak plasma concentration of 220 micromoles/Liter. Intravenous administration of the same dose of vitamin C (18 grams/day) can increase plasma concentration 25 times. Even larger doses (50-100 grams/day) can increase the plasma concentration levels to 14,000 micromoles/Liter. At 1,000 micromoles/Liter, vitamin C is toxic to cancer cells, but not toxic to normal, healthy cells .
Vitamin C treatment was first suggested as a cancer treatment in the 1950’s because of its role in collagen production. Since cancer patients are often depleted of vitamin C, scientists believed that the vitamin C would protect normal tissues and by replenishing vitamin C level immune system function would be enhanced .
In one study, scientists observed a four-fold survival rate in terminal cancer patients who were treated with high-dose vitamin C IV’s. The researchers who conducted the study observed a survival rate one-third higher for the patients who were given high-dose vitamin C. For the patients who died during the study, their average survival time was more than 20 times higher than it was for terminal cancer patients who did not receive vitamin C treatments .
There are rare instances that have been reported where patients with multiple, rapidly proliferating tumors were given high-dose vitamin C, which caused widespread tumor hemorrhage and necrosis that ultimately caused the patient to die. Deaths like these from high-dose vitamin C are rare, but despite their tragic nature, they demonstrate the power of vitamin C to cause cancer cells to die .
How Intravenous Vitamin C Is Administered
The half-life of vitamin C is only 2 hours which is why it has to be administered in high doses via IV, otherwise, when administering vitamin C by mouth, the blood concentration never reaches a high enough level to be beneficial in terms of cancer cells. Clinical trials at the University of Iowa in Iowa City have examined the effect of giving 800 to 1,000 times the daily recommended dose of vitamin C to brain and lung cancer patients. The research has shown that vitamin C at 20,000 micromoles disrupts cancer cell metabolism in glioblastoma and non-small-cell lung cancer. Most normal adults have about 70 micromoles of circulating vitamin C .
Possible Negative Effects
Intravenous vitamin C treatments are generally well tolerated, but some patients may experience side effects such as brief episodes of high blood pressure or dry mouth .
Other Important information
The Nobel Prize winner, Linus Pauling and Dr. Ewen Cameron did a study that showed that 10 grams of vitamin C administered via IV could extend the life of cancer patients six-fold .
Clinics That Offer Intravenous High-Dose Vitamin C
The Riordan Clinic (available in 3 locations):
3100 N. Hillside Ave.
Witchita, KS 67219
1010 E 17th Street
Hays, KS 67601
6300 W 143rd Street, Suite #205
Overland Park, KS 66223
2000 Olathe Boulevard
Kansas City, KS 66160
90 Adams Place Delmar, NY 12054
 National Cancer Institute (2018). High-Dose Vitamin C (PDQ™)—Patient Version. Retrieved March 15, 2018 from https://www.cancer.gov/about-cancer/treatment/cam/patient/vitamin-c-pdq
 Sandoiu, A. (2017). High-dose vitamin C makes cancer treatment more effective, trial shows. Retrieved March 15, 2018 from https://www.medicalnewstoday.com/articles/316643.php
 Cancer Tutor (2017). High Dose Intravenous Vitamin C (IVC). Retrieved March 15, 2018 from https://www.cancertutor.com/vitaminc_ivc/
 Schoenfeld, J. D. et al (2017). O2⋅− and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate
Retrieved March 15, 2018 from http://www.cell.com/cancer-cell/fulltext/S1535-6108(17)30062-4
 Padayatty, S. J., Riordan, H. D., Hewitt, S. M., Katz, A., Hoffer, J. L, Levine, M. (2006). Intravenously administered vitamin C as cancer therapy: three cases. Retrieved March 15, 2018 from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1405876/
 Riordan, N. H., Riordan, H. D., Meng, X., Li, Y., & Jackson, J. A. (1995). Intravenous Ascorbate as a Tumor Cytotoxic Chemotherapeutic Agent. Retrieved March 15, 2018 from http://web.archive.org/web/20080315233302/http://www.seanet.com:80/~alexs/ascorbate/199x/riordan-nh-etal-med_hypotheses_1995-v44-p207.htm
 Cameron, E. & Pauling, L. (1976). Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Retrieved March 15, 2018 from
 Creagan, E. T., Moertel, C. G., O’Fallon, J. R., Schutt, A. J., O’Connell, M. J., Rubin, J., Frytak, S. (1979). Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. Retrieved March 15, 2018 from https://www.ncbi.nlm.nih.gov/pubmed/384241
 Moertel, C. G., Fleming, T. R., Creagan, E. T., Rubin, J., O’Connell, M. J., Ames, M. M. (1985). High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. Retrieved March 15, 2018 from https://www.ncbi.nlm.nih.gov/pubmed/3880867